钻孔法微小头发移植体治疗秃发的临床研究

目的:探讨使用钻孔微小头发移植体移植治疗秃发的临床效果。方法:1999年8月～2000年5月对28例患者进行钻孔法自体微小头发移植术治疗秃发。其中雄性秃发18例,疤痕性秃发3例,前额发际线过高7例。结果:18例患者经过术后6～9个月的随访,移植头发存活率高。其中7例患者进行2次种植,1例患者进行4次种植。结论:应用钻孔法微小头发移植体治疗秃发,移植头发易存活,外观自然,但一次种植仍显稀疏,往往需二次或多次种植。     

自体表皮移植术治疗白癜风52例疗效分析

目的：观察白癜风自体表皮移植治疗术的疗效，探讨其成功的关键环节及失败的常见原因。方法：选取符合手术指征的白癜风患者52例，行自体表皮移植治疗术，于手术3个月后随访观察疗效。结果：52例白癜风患者治愈率82．69％，显效率100％，患者满意率100％。结论：采用自体表皮移植术治疗稳定期白癜风，手术安全，病人痛苦少，术后见效快，值得在临床上推广。     

头发移植术治疗脂溢性脱发51例效果观察

笔者采用ＷＹＺ－Ｉ型微型牙科钻磨机改装成空管环形钻刀，对５１例脂溢性脱发患者实施了头发移植术，疗效满意，现报告如下：一般资料：５１例脂溢性脱发患者中，男性４８例（９４％），女性３例（６％）；年龄２８～４７岁，平均３６９岁；病程２５～１３年，平均５...     

细胞自体体外再生技术与负压吸疱表皮移植术在白癜风临床治疗中的优劣对比

目的 对比细胞自体体外再生技术(ReCell技术)和负压吸疱表皮移植术治疗白癜风的临床疗效及安全性。方法 选取2018年1月—2022年12月昆明白癜风皮肤病医院就诊的稳定期混合型白癜风患者60例，白斑面积均>40 cm²为研究对象，随机分为A、B两组，每组30例，A组采用细胞自体体外再生技术，B组采用负压吸疱表皮移植术，对术后两组临床疗效和不良反应进行比较。结果 术后3个月，A组30例，痊愈16例，显效8例，好转3例，无效3例，有效率80.00%;B组30例，痊愈8例，显效5例，好转2例，无效15例，有效率43.33%;A组有效率高于B组，两组比较差异有统计学意义(P<0.05)。结论 细胞自体体外再生技术治疗稳定期白癜风疗效优于负压吸疱表皮移植术，值得临床选择应用。     

自体疣埋植治疗尖锐湿疣及其对机体T细胞亚群的影响

目的：研究自体疣组织埋植治疗尖锐湿疣（CA）疗效及其对机体细胞免疫功能的影响。方法：将98例尖锐湿疣患者随意分成两组，A组采用自体疣组织埋植＋CO2激光治疗，B组单用CO2激光治疗；两组治疗前后均检测外周血T淋巴细胞亚群。结果：A组复发率低，疗效优于B组，A组与B组比较，CD8^ 细胞数量明显下降（P＜0．05），CD4^ 细胞数量及CD4^ /CD8^ 比值明显提高（P＜0．05）。结论：自体疣组织埋植治疗尖锐湿疣疗效好，能降低复发率，其机理可能是自体疣组织埋植能改善CA患者的细胞免疫功能。     

自体表皮移植治疗色素脱失性皮肤病的追踪观察

本文对自体表皮移植治疗的46例色素脱失性皮肤病病人(其中白癜风40例、晕痣5例、斑驳病1例)，通过问卷及临床复诊进行追踪观察。了解自体表皮移植术治疗色素脱失性皮肤病的远期疗效。结果：46例中显效78．97％，有效14．56％，无效6．47％。经2．8年随访，31例局限型及7例节段型白癜风患者未见复发。自体表皮移植术是治疗稳定期局限型及节段型白癜风的首选方法。     

自体表皮移植术后加PUVA联合治疗白癜风

我们设计了自体表皮移植术加ＰＵＶＡ(光化学疗法 )治疗白癜风的方案 ,临床对照观察 52例 ,取得了满意的疗效。现将结果报告如下。病例与方法1.临床资料　 52例均为本院门诊病人 ,男 2 2例 ,女 30例。年龄 9～ 6 1岁。病程 3月～ 10年。选择皮损局限或节段型 (一般不超过体表面积的 10 % )且近期 (3个月 )皮损无扩展及新白斑出现的病例 ,以往曾用各种方法治疗无效。 52例病人以半随机的方式分为两组 ,Ａ组 2 0例 ,采用表皮移植加ＰＵＶＡ ;Ｂ组 32例 ,单纯采用表皮移植为对照 ,两组患者的年龄、病程及病情基本一致。2 .方法　自体表皮移植术…     

CO2激光在自体表皮移植术治疗白癜风中的应用

近年来我科开展自体表皮移植术治疗白癜风,供皮区采用负压吸疱法,在白斑处用CO2激光去除表皮进行移植,共治疗50例白癜风患者,报告如下. 临床资料:50例稳定期白癜风患者,男24例,女26例,年龄13～52岁;病程6个月～25年;局限型40例,节段型7例,泛发型3例,共96个白斑区,皮损大小0.5～50cm2不等.     

毛发疾病

20053328男性型秃发头发移植后性激素受体的变化/陈学杰(武汉大学人民医院整形外科),余墨声,王松山…∥中华医学美学美容杂志.-2005,11(3).-167~169采用荧光组织化学方法,对13例接受自体头发移植术患者的供、受区头皮及头发对应组织中雌、雄激素受体进行检测并对比。结果头发移植术后,各实验对象供区与受区相应移植组织中,其性激素受体的含量对比,差异无统计学意义。认为供体毛胚移植到受区后,其局部组织性激素受体的含量不会发生改变。从另一角度佐证了头皮及头发性激素受体含量的异常在男性型秃发中起重要作用。表1参12。(时岩)20053329皖…     

自体表皮移植治疗白癜风112例临床观察

白癜风为一种常见病,治疗方法虽多,但对某些类型疗效不甚满意,１９８５年国外学者采用自体表皮移植治疗白癜风获得成功,表明黑素细胞可以通过表皮移植到白斑处,我科自１９９５年１１月～１９９９年４月采用自体表皮移植治疗白癜风病人 １１２例（４８７区）,取得满意疗效,现报告如下：１临床资料 １１２例均为本科门诊病人,男３９例,女73例;男女比为１：１．８７;年龄最小７岁,最大５９岁,平均２８．４岁;病程最短５月,最长３２年,平均３．５年;根据全国色素病学组１９９４年制订的白癜风分型（草案）标准,节段型 ５２例…     

Adenosine increases anagen hair growth and thick hairs in Japanese women with female pattern hair loss: A pilot,double‐blind,randomized, placebo‐controlled trial

Adenosine upregulates the expression of vascular endothelial growth factor and fibroblast growth factor‐7 in cultured dermal papilla cells. It has been shown that, in Japanese men, adenosine improves androgenetic alopecia due to the thickening of thin hair due to hair follicle miniaturization. To investigate the efficacy and safety of adenosine treatment to improve hair loss in women, 30 Japanese women with female pattern hair loss were recruited for this double‐blind, randomized, placebo‐controlled study. Volunteers used either 0.75% adenosine lotion or a placebo lotion topically twice daily for 12 months. Efficacy was evaluated by dermatologists and by investigators and in phototrichograms. As a result, adenosine was significantly superior to the placebo according to assessments by dermatologists and investigators and by self‐assessments. Adenosine significantly increased the anagen hair growth rate and the thick hair rate. No side‐effects were encountered during the trial. Adenosine improved hair loss in Japanese women by stimulating hair growth and by thickening hair shafts. Adenosine is useful for treating female pattern hair loss in women as well as androgenetic alopecia in men.     

Cross-sectional study of hair loss patterns in 122 Korean systemic lupus erythematosus patients: a frequent finding of non-scarring patch alopecia

Although non-scarring diffuse hair loss has been frequently observed in systemic lupus erythematosus (SLE) patients, the pattern of hair loss with regard to its frequency in SLE has been rarely studied. The aim of this cross-sectional study was to evaluate the hair loss patterns in SLE during the course of disease. We evaluated 122 SLE patients (age range, 13-71 years; mean age, 32.7 +/- 10.6; female : male ratio, 12.6:1), by conducting interviews about hair loss patterns before and after a diagnosis of SLE using a questionnaire format. History taking and physical examinations were done at the time of interview, and photographs were taken to discriminate the active LE-specific scarring hair loss from the LE-nonspecific diffuse hair loss. Frequency and correlation analysis were performed on the data from the interviews and photographs for determining their relation with the SLE Disease Activity Index (SLEDAI). We found that 104 patients experienced at least one hair loss event before or during the course of SLE. Eighteen patients experienced patch alopecia, including eight who experienced this malady both before and after the diagnosis; thus, the overall prevalence of patch alopecia was 14.8% (18/122). Eighty-six patients experienced hair loss after diagnosis, of which non-scarring diffuse hair loss was the most common pattern (65.1%, 56/86) followed by non-scarring patch alopecia (15.1%, 13/86). The interview survey failed to identify a statistically significant relationship between the hair loss pattern and the SLEDAI. Our results suggest that non-scarring patch alopecia is also an important pattern in SLE that should be included in the differential diagnosis of alopecia areata and confirmed by histopathological examination.     

The surgical treatment of cicatricial alopecia

ABSTRACT:   Surgical correction of cicatricial alopecia can yield exceptional results when performed in the appropriate clinical scenario. To facilitate determination of the most suitable corrective therapy, we propose two new categories of cicatricial alopecia: "unstable" and "stable." Unstable cicatricial alopecia is intermittent and results in possible subsequent scarring hair loss in either new or old areas. Stable cicatricial alopecia, on the other hand, refers to fixed permanent scarring. While surgical excision is preferred to hair transplantation for both categories of cicatricial alopecia, this preference is even stronger in cases of unstable cicatricial alopecia due to its intermittent and progressive nature. Regardless of which corrective technique is used, analysis of specific physical patient characteristics coupled with a careful view towards the possible evolution of male pattern baldness or female pattern hair loss are essential to achieve superior long-term results. Herein we also outline guidelines for identifying these physical traits as well as for performing hair transplantation and surgical excision in order to achieve optimal cosmetic outcomes and minimize postoperative complications.     

Intradermal injections with 0.5% minoxidil for the treatment of female androgenetic alopecia: A randomized,placebo‐controlled trial

Female androgenetic alopecia is one cause of alopecia in women, although the ideal treatment for this condition remains far from defined. The objective of this study was to evaluate the efficacy and safety of intradermal injections with 0.5% minoxidil for the management of female androgenetic alopecia in a randomized, placebo‐controlled trial. A total of 54 women diagnosed with female androgenetic alopecia were divided into two groups: one group received intradermal injections of 0.5% minoxidil, and the other received 0.9% saline. Biopsy, trichogram, Trichoscan (Tricholog GmbH, Freiburg, Germany), and self‐assessment findings were used to evaluate the outcomes of treatment with minoxidil. In the treated group, there was a significant increase in the terminal‐to‐vellus hair ratio (P < .001) and in the percentage of anagen hairs (P = .048) and an improvement in hair loss and volume (P = .021 and P = .028, respectively). These results show that intradermal injections with minoxidil were more effective than placebo (P < .001) in the treatment of female androgenetic alopecia with a good safety profile.     

Frictional hair loss in Iraqi patients

A total of 50 Iraqi male patients with frictional hair loss were studied. Their ages ranged from 27-55 years with a mean +/- SD of 40.60 +/- 7.82 years. The age of onset ranged from 26-50 years with a mean +/- SD of 38 +/- 7.3 years. The duration of disease was 1-5 years, mean +/- SD 2.2 +/- 1.3. Middle age was the most common age group affected. Patterns of hair loss were as follows; bilateral thighs & legs 13 (26%), bilateral thighs alone in 9 patients (18%), bilateral shins & calves (legs) in 4 patients (8%), abdomen alone in 8 patients (16%), thigh and abdomen 4 (8%) patients, legs & abdomen 4 (8%) patients, and all sites in 12 patients (24%). The pattern of patchy hair loss showed some etiological preference. It was found to be due to continuous pressure from socks, trousers and bed. Skin biopsies from five patients showed apparently normal histology. Twenty-six (52%) of the cases were healthy. There were no important medical or dermatological associations, such as alopecia areata or peripheral neuropathy in any patient although unrelated medical conditions were seen in 24 (48%). To the best of our knowledge, this type of patchy hair loss has attracted very little attention in the past, and the literature appeared to be deficient in references to this problem.     

Topical application of ketoconazole stimulates hair growth in C3H/HeN mice

Ketoconazole (KCZ) is an imidazole anti-fungal agent that is also effective in topical applications for treating seborrheic dermatitis and dandruff. Recently, topical use of 2% KCZ shampoo has been reported to have had a clinically therapeutic effect on androgenetic alopecia. The present study was conducted with the purpose of quantitatively examining the stimulatory effect of KCZ on hair growth in a mouse model. Coat hairs on the dorsal skin of seven week-old male C3H/HeN mice were gently clipped, and either 2% KCZ solution in 95% ethanol or a vehicle solution was topically applied once daily for three weeks. The clipped area was photographed, and the ratio of re-grown coat area was then calculated. The results demonstrated that 2% KCZ had a macroscopically significant stimulatory effect compared with the vehicle group (p<0.01, n=10). Repeated experiments showed similar effects, confirming the efficacy of KCZ as a hair growth stimulant. Although the therapeutic mechanism of topical KCZ for hair growth is unclear, our results suggest that topical applications of the substance are useful for treating seborrheic dermatitis accompanied by hair regression or male pattern hair loss.     

不同深度微针联合外用米诺地尔酊治疗男性雄激素性脱发的疗效观察

目的 观察不同深度微针联合外用米诺地尔酊治疗男性雄激素性脱发的临床疗效以及安全性。方法 纳入2020年6月至2021年6月河南科技大学第一附属医院皮肤科门诊男性雄激素性脱发患者90例,随机分为A组(n=30)、B组(n=30)和C组(n=30)。A组仅外用5%米诺地尔酊治疗,B组予0.5 mm深度电动微针针刺联合外用米诺地尔酊治疗;C组予1 mm深度电动微针针刺联合外用米诺地尔酊治疗。治疗12周后观察临床疗效及不良反应情况。结果 治疗12周后,三组患者毛发密度、毛发直径均较治疗前明显改善(均P<0.05),B组和C组均明显优于A组(均P<0.05)。B组和C组患者治疗后自我评估头发生长改善评分均明显优于A组(均P<0.05)。A、B、C三组患者不良反应发生率分别为6.67%、6.67%和26.67%,C组明显高于A组和B组(χ²=6.92,P=0.031)。结论 0.5 mm深度微针针刺联合外用米诺地尔酊治疗男性雄激素性脱发疗效显著,安全性好,是男性雄激素性脱发患者新的治疗选择。     

Hair restoration approaches for early onset male androgenetic alopecia

Society places great emphasis on the presence of hair. Some degree of hair loss is accepted as a normal part of the aging process, in line with the observation that more than 50% of men will develop androgenetic alopecia by the age of 50 years. However, it is possible to understand the psychosocial isolation and distress felt by men with a strong familial predisposition to androgenetic alopecia, who tend to display hair loss in their late teens or twenties. There are currently two drugs which have been licensed for the treatment of male androgenetic alopecia: oral finasteride and topical minoxidil solution which are effective to some extent. Furthermore, upon discontinuing treatment, any gain that has been achieved is quickly lost. Added to which there is an entire market of unproven over the counter products: advertised in the electronic media, local hair salons, and various departmental stores. In this review, we highlight the important advances in the management of male androgenetic alopecia with emphasis on approaches that can lead to more successful and long‐term hair restoration for young adults. In particular, we discuss the evidence supporting the use of the follicular unit grafting technique in conjunction with medical treatment before and after the procedure. Moreover, some other alterations of this most popular state of the art hair restoration technique have been mentioned briefly. As a result, patients and physicians seem equally satisfied from this procedure for its naturally looking results which are cosmetically more acceptable and esthetically pleasing for longer period of time.     

毛发移植术治疗秃发疗效分析

目的应用自体毛发移植术对秃发进行治疗并观察中、远期疗效。方法选择本院2000年2月~2005年7月的638例患者,其中雄激素源性秃发522例,瘢痕性秃发116例,均采用自体毛发移植术治疗,并定期随访。结果移植毛囊成活率分别为96.83%(男性雄激素源型秃发),95.73%(女性雄激素源型秃发),90.52%(瘢痕性秃发)。随访6~68个月未见移植毛发再次脱落。医生满意度为95.14%(607/638),患者满意度为97.49%(622/638)。结论毛发移植技术是一项安全、可靠、有效的治疗方法。可用于雄激素源性秃发和瘢痕性秃发的治疗,远期疗效较好。     

Randomized clinical trial comparing 5% and 1% topical minoxidil for the treatment of androgenetic alopecia in Japanese men

Minoxidil is efficacious in inducing hair growth in patients with androgenetic alopecia by inducing hair follicles to undergo transition from the early to late anagen phase. Although the efficacy of 1% topical minoxidil has been confirmed in Japan, no controlled study of 5% topical minoxidil has been conducted using male Japanese subjects. The objective of this trial was to verify the superiority in clinical efficacy of 5% topical minoxidil to 1% topical minoxidil in a double-blind controlled study with male, Japanese androgenetic alopecia patients as the subjects. The trial included 300 Japanese male patients aged 20 years or older with androgenetic alopecia who were administered either 5% topical minoxidil ( n  = 150) or 1% topical minoxidil ( n  = 150) for 24 weeks. The mean change from the baseline in non-vellus hair/cm², the primary efficacy variable, was 26.4 ( n  = 142) in the 5% topical minoxidil group and 21.2 ( n  = 144) in the 1% topical minoxidil group at 16 weeks, the main time point for the evaluation. The difference between the groups was significant ( P  = 0.020). The incidence of adverse events was 8.7% (13/150) in the 5% group and 5.3% (8/150) in the 1% group, with no significant difference between the groups (χ²-test: P  = 0.258). Our findings confirmed the superiority of 5% topical minoxidil to 1% topical minoxidil in treating Japanese men with androgenetic alopecia.